Meril
Meril, a leader in cardiovascular and structural heart solutions, known for its next-generation transcatheter heart valve technologies, has announced the launch of its next-generation Myval Octapro THV.
Meril says its Myval Octapro THV underscores dedication to redefining TAVR technology and shaping the future of structural heart care.
The company claims the Myval THV series has a 'profound impact' & has been 'instrumental' in advancing transcatheter aortic valve replacement (TAVR) therapy.
Characterised by reduced frame foreshortening leading to higher operator control and predictive deployment; availability of a large size matrix comprising of conventional, intermediate and extra-large valve diameters allowing better bioprosthetic valve sizing for individual patient and supported by a large pool of clinical evidence substantiates the day-to-day clinical utility of the device globally.
The clinical efficacy of the Myval THV series was demonstrated through the LANDMARK RCT published in THE Lancet(Baumbach et. al. Volume 403, Issue 10445, P2695-2708, June 22, 2024), conducted by renowned clinicians worldwide including 768 real world patients in 16 countries across 31 centers.
The primary endpoint of the LANDMARK RCT demonstrated non-inferiority of the Myval THV series compared with contemporary THV series. Importantly, effective orifice area (EOA) of conventional sizes 23, 26, 29 mm of Myval THV series were significantly better than contemporary balloon expandable series says the company.
48% of Myval THV series implants were intermediate-size devices which are not offered by contemporary THV technologies. Both the intermediate and XL diameters are unique to context of TAVR technology.
Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences said: "At Meril, our commitment to developing and delivering state-of-the-art, best-in-class TAVR solutions remains unwavering. The trust the global clinical community has placed in the Myval THV series is a testament to its profound positive impact on patient outcomes, and we are dedicated to building on this legacy.
"With the launch of the Myval Octapro THV, doctors and patients worldwide will continue to benefit from Meril's advanced transcatheter heart valve portfolio."
